Status:
COMPLETED
A Study of Dulaglutide in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre fil...
Eligibility Criteria
Inclusion
- Overtly healthy as determined by medical history and physical examination at time of screening
- Have a body mass index of greater than or equal to (≥) 23 kilograms per meter squared (kg/m²) inclusive
Exclusion
- Have known allergies to dulaglutide, glucagon-like peptide-1 (GLP-1) related compounds, or any components of the formulation
- Have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
- Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder (e.g., relevant esophageal reflux or gall bladder disease) or any gastrointestinal disease which impacts gastric emptying (e.g., gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs
Key Trial Info
Start Date :
December 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 6 2018
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT03363906
Start Date
December 7 2017
End Date
June 6 2018
Last Update
July 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Dallas
Dallas, Texas, United States, 75247